Trade Name Trasylol
Orphan Indication For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary coronary artery bypass graft surgery where the risk of bleeding is especially high (impaired hemostasis) or where transfusion is unavailable or unacceptable
USA Market Approval USA
USA Designation Date 1993-11-17 00:00:00
Sponsor Bayer Corporation;Pharmaceutical Division, 400 Morgan Lane;West Haven, Connecticut, 06516